The efficacy of alendronate in reducing the risk for vertebral fracture in Japanese patients with osteoporosis: A randomized, double-blind, active-controlled, double-dummy trial

Current Therapeutic Research - Clinical and Experimental

Volumn 63, Issue 9, 2002, Pages 606-620

  Kazuhiro, Kushida ^a   Masataka, Shiraki ^b   Toshitaka, Nakamura ^c   Hideaki, Kishimoto ^d   Hirotoshi, Morii ^e   Kichizo, Yamamoto ^f   Kiyoshi, Kaneda ^g   Masao, Fukunaga ^h   Tetsuro, Inoue ⁱ   Mituyoshi, Nakashima ^a   Hajime, Orimo ^j  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b RESEARCH INSTITUTE AND PRACTICE FOR INVOLUTIONAL DISEASES   (Japan)

^c UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^d SAN IN ROSAI HOSPITAL   (Japan)

^e Japan Osteoporosis Society   (Japan)

^f Hakuai Hospital   (Japan)

^g Bibai Rosai Hospital   (Japan)

^h KAWASAKI MEDICAL SCHOOL   (Japan)

ⁱ Aoyama General Hospital   (Japan)

^j Tokyo Metropolitan Institute of Gerontology   (Japan)

more..

Author keywords

Alendronate; Alfacalcidol; Clinical trial; Japanese; Osteoporosis; Vertebral fracture

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; PLACEBO;

ABDOMINAL DISCOMFORT; ADULT; AGED; ARTICLE; BONE DENSITY; BONE MINERAL; BONE STRENGTH; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GASTRITIS; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SPINE RADIOGRAPHY; STOMACH DISEASE; STOMACH PAIN; TREATMENT OUTCOME; TREATMENT PLANNING; VERTEBRA FRACTURE;

EID: 0036747512     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(02)80065-0     Document Type: Article

References (39)

1. Kanis JA, Delmas P, Burckhardt P, et al, for the European Foundation for Osteoporosis and Bone Disease. Guidelines for diagnosis and management of osteoporosis. Osteoporosis Int. 1997;7:390-406.
2. Johnell O. The socioeconomic burden of fractures: Today and in the 21st century. Am J Med. 1997;103:20S-26S.
3. Cooper C, Campion G, Melton LJ 3rd. Hip fractures in the elderly: A world-wide projection. Osteoporosis Int. 1992;2:285-289.
4. Orimo H, Hashimoto T, Yoshimura N, et al. Nationwide incidence survey of femoral neck fracture in Japan, 1992. J Bone Miner Metab. 1997;15:100-106.
5. Ross PD. Clinical consequences of vertebral fractures. Am J Med. 1997;103:30S-43S.
6. Ross PD, Fujiwara S, Huang C, et al. Japanese women in Hiroshima have greater vertebral fracture prevalence than Caucasians or Japanese-Americans in the US. Int J Epidemiol. 1995;24:1171-1177.
7. Jinbayashi H, Aoyagi K, Ross PD, Shindo S. Prevalent vertebral fracture and other predictors of physical impairment. J Bone Miner Res. 2000;15(Suppl 1):S295. Abstract.
8. Hagino H, Yamamoto K, Ohshiro H, et al. Changing incidence of hip, distal radius, and proximal humerus fractures in Tottori Prefecture, Japan. Bone. 1999;24:265-270.
9. Lau EM, Lee JK, Suriwongpaisal P, et al. The incidence of hip fracture in four Asian countries: The Asian Osteoporosis Study (AOS). Osteoporosis Int. 2001;12:239-243.
10. Iga T, Dohmae Y, Endo N, Takahashi HE. Increase in the incidence of cervical and trochanteric fractures of the proximal femur in Niigata Prefecture, Japan. J Bone Miner Metab. 1999;17:224-231.
11. Koh LK, Saw SM, Lee JJ, et al. Hip fracture incidence rates in Singapore, 1991-1998. Osteoporosis Int. 2001;12:311-318.
12. Ross PD, Huang C. Hip fracture incidence among Caucasians in Hawaii is similar to Japanese. A population-based study. Aging (Milano). 2000;12:356-359.
13. Huang C, Ross PD, Wasnich RD. Vertebral fracture and other predictors of physical impairment and health care utilization. Arch Intern Med. 1996;156:2469-2475.
14. Nevitt MC, Thompson DE, Black DM, et al, for the Fracture Intervention Trial Research Group. Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Arch Intern Med. 2000;160:77-85.
15. Shiraki M, Kushida K, Fukunaga M, et al, for the Alendronate Research Group. A placebo-controlled, single-blind study to determine the appropriate alendronate dosage in postmenopausal. Japanese patients with osteoporosis. Endocr J. 1998;45: 191-201.
16. Shiraki M, Kushida K, Fukunaga M, et al, for the Alendronate Phase III Osteoporosis Treatment Research Group. A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. Osteoporosis Int. 1999;10:183-192.
17. Kung AW, Yeung SS, Chu LW. The efficacy and tolerability of alendronate in postmenopausal osteoporotic Chinese women: A randomized placebo-controlled study. Calcif Tissue Int. 2000;67:286-290.
18. Lau EM, Woo J, Chan YH, Griffith J. Alendronate prevents bone loss in Chinese women with osteoporosis. Bone. 2000;27:677-680.
19. Wasnich RD, Ross PD, Thompson DE, et al. Skeletal benefits of two years of alendronate treatment are similar for early postmenopausal Asian and Caucasian women. Osteoporosis Int. 1999;9:455-460.
20. Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993;8:1137-1148.
21. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282:637-645.
22. Liberman UA, Weiss SR, Bröll J, et al, for the Alendronate Phase III Osteoporosis Treatment Study Group. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 1995;333:1437-1443.
23. Black DM, Cummings SR, Karpf DB, et al, for the Fracture Intervention Trial Research Group. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348:1535-1541.
24. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA. 1998;280:2077-2082.
25. Hochberg M. Preventing fractures in postmenopausal women with osteoporosis: A review of recent controlled trials of antiresorptive agents. Drugs Aging. 2000;17: 317-330.
26. Black DM, Thompson DE, Bauer DC, et al, for the FIT Research Group. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. J Clin Endocrinol Metab. 2000;85:4118-4124.
27. Pols HA, Felsenberg D, Hanley DA, et al, for the Fosamax International Trial Study Group. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study. Osteoporosis Int. 1999;9:461-468.
28. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000;343:604-610.
29. McClung M, Clemmesen B, Daifotis A, et al, for the Alendronate Osteoporosis Prevention Study Group. Alendronate prevents postmenopausal bone loss in women without osteoporosis: A double-blind, randomized, controlled trial. Ann Intern Med. 1998;128:253-261.
30. Ravn P, Bidstrup M, Wasnich RD, et al. Alendronate and estrogen-progestin in the long-term prevention of bone loss: Four-year results from the Early Postmenopausal Intervention Cohort study. A randomized, controlled trial. Ann Intern Med. 1999;131: 935-942.
31. Downs RW Jr, Bell NH, Ettinger MP, et al. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women. J Clin Endocrinol Metab. 2000;85:1783-1788.
32. Rosen CJ, Bonnick SL, Miller PD, et al. Treatment of osteoporosis in postmenopausal women: Alendronate vs intranasal calcitonin. J Bone Miner Res. 2000;14(Suppl 1): S400. Abstract.
33. Aoyagi K, Shiraki M, Ito M, Nakamura T. Statistical analysis for comparing antifracture efficacy among antiresorptive agents. Alendronate versus alfacalcidol and calcitonin. Clin Drug Invest. 2001;21:415-422.
34. Guyatt GH. Evidence-based management of patients with osteoporosis. J Clin Densitom. 1998;1:395-402.
35. Pal B. Questionnaire survey of advice given to patients with fractures. BMJ. 1999; 318:500-501.
36. Freedman KB, Kaplan FS, Bilker WB, et al. Treatment of osteoporosis: Are physicians missing an opportunity? J Bone Joint Surg Am. 2000;82:1063-1070.
37. Solomon DH, Levin E, Helfgott SM. Patterns of medication use before and after bone densitometry: Factors associated with appropriate treatment. J Rheumatol. 2000;27: 1496-1500.
38. International Osteoporosis Foundation. How fragile is her future? Available at: http://www.osteofound.org/publications/pdf/how_fragile_is_her_future.pdf. International Osteoporosis Foundation, Lyon, 2000. Accessed July 1, 2002.
39. Fujiwara S, Masunari N, Suzuki G, Ross PD. Performance of osteoporosis risk indices in a Japanese population. Curr Ther Res Clin Exp. 2001;62:586-594.